Thanks, mightpirate and Trae for raising up the issue again.
Before I begin, I have to admit that my findings are actually based on very brief google and baidu search with keyword such as 阜康仁 and fokangren. And as a CDY investor myself, I hope that Im wrong and you guys are right and Im more than happy to be corrected.
You guys dig out, pretty much what i had read, amid in much deeper depth.
First, do not trust what was written on their official site, remember this is China, they can write whatever they want, and it cost them nothing.
Instead, I go for the more solid evidences:
1. Is a private company, first what caught my attention is their registered capital.
https://www.riskstorm.com/company/91110106735583702D
A million yuan. Ok that was 16 years ago.
I couldnt find much development news based on my findings, and I have to thank Mr Pirate for those info. They did collaborate with 泸县(place name) county gov for the medical park. Again, I will not believe the amount involved, this is China again, gov like to balloon the figures. So instead of believing what was put into our mouth, I did my own research and question myself, after so many years, what product they made?
If they are a generic medicine maker, what is their product name called? User feedback etc, I tried to search through chinese forums, yield nothing. So I sincerely hope you guys can help me out and prove me wrong.
2. They claim that they are in frontal clinical research activities. Lets put this claim into test.
http://www.fukangren.com/chuangxinyaoyanfapingtai.html
其中3个产品已经进入3期临床阶段,其余基本完成临床前研究
^^3 products entered stage 3 clinical trials
Stage 3 trials drugs that I can find:
http://www.fukangren.com/chuangxinyaowu.html
Column 1 Column 2 Column 3 Column 4 0 PIA-206 幽门螺旋杆菌感染 阿莫西林复方制剂,依从性好,疗效(70%有效率)优于传统标准组合(63%有效率),且无明显不良反应 3期临床试验
Column 1 Column 2 Column 3 Column 4 0 W-Gel 可预防和治疗细菌性阴道炎(BV) 凝胶,无全身效应,可与避孕套一起使用 3期临床试验
Column 1 Column 2 Column 3 Column 4 0 THL-01 避孕 提高睾酮水平,降低骨质疏松风险 3期临床试验
Column 1 Column 2 Column 3 Column 4 0 舌下舒芬太尼 疼痛 舌下含片,非侵入性给药 3期临床试验
Column 1 Column 2 Column 3 Column 4 0 Colipin 多发性骨髓瘤 海洋天然产物 3期临床试验
Column 1 Column 2 Column 3 Column 4 0 DP-438 银屑病 新机制 3期临床试验
At first, I search them on https://clinicaltrials.gov/
I went to the advance search, search for the company related stage 3 trials info, no result.
Ok, how about chinese clinical trial? Maybe they are not registered in global platform.
https://db.yaozh.com/linchuangshiyan
At the 申办单位 (organiser) key in 阜康仁 fokangren, fukangren
NO RESULT.
Ok, on this bits, I hope im wrong again. Hope anyone that do know better, correct it.
Lastly regarding the patent, pretty much not innovative, those are just some manufacturing process improvement patent. Eg hey i can use another way to produce aspirin, i'll patent it!
Whether it translate into better cost efficiency, unknown, I would not draw that conclusion.
Others are chinese med preparing method patents.
Didnt bother with any chinese traditional med search, are there any? Pls enlighten.
To sum up, I still believe they some how involve in some sort of manufacturing practise, details about it, I couldnt find out anything through internet, and I have serious doubt about this company ongoing viability, not going bankrupt but certainly do not have those hospital, pharmacy channel as cellmid hoped for.
If they are that good, they should be listed, this belongs to new industry area for China, and chinese government, chinese venture capital will flood this company with money.
My 2.5 cents.
- Forums
- ASX - By Stock
- AN1
- China deal..... Fukang Ren?
China deal..... Fukang Ren?, page-36
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online